Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What are today's orphaned vaccines?

H Wilde1

  • 1Queen Saovabha Memorial Institute and Department of Medicine, Chulalongkorn University Hospital, Bangkok, Thailand. henry@mail.redcross.or.th

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|August 7, 2001
PubMed
Summary

High development costs and regulatory hurdles discourage vaccine production for tropical diseases. Developing countries need local manufacturing capabilities and technology transfer to ensure access to life-saving vaccines.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gender- and Sexuality-Minoritised Adolescents in DBT: A Reflexive Thematic Analysis of Minority-Specific Treatment Targets and Experience.

Cognitive behaviour therapist·2023
Same author

Incidental Discovery of Accelerated Atrioventricular Conduction in Healthy Adults.

Canadian Medical Association journal·2010
Same author

One or three intradermal injections within one week for rabies pre-exposure immunization.

Developments in biologicals·2008
Same author

Ten-day observation of live rabies suspected dogs.

Developments in biologicals·2008
Same author

Sex- and age-related differences in rabies immunoglobulin hypersensitivity.

Transactions of the Royal Society of Tropical Medicine and Hygiene·2006
Same author

Survival of neutralizing antibody in previously rabies vaccinated subjects: a prospective study showing long lasting immunity.

Vaccine·2006

Area of Science:

  • Biotechnology
  • Vaccinology
  • Global Health

Background:

  • Rising development costs and extended timelines for new biological agents pose significant challenges.
  • Complex global regulatory requirements increase barriers and costs for early international market entry.
  • Manufacturers exhibit reluctance to invest in vaccines for tropical diseases primarily affecting low-income countries.

Purpose of the Study:

  • To analyze the economic and regulatory factors hindering vaccine development for neglected tropical diseases.
  • To highlight the need for sustainable vaccine production models in tropical regions.
  • To emphasize the critical role of technology transfer in bridging the research-to-production gap.

Main Methods:

  • Analysis of vaccine development costs and market access challenges.

Related Experiment Videos

  • Review of regulatory landscapes impacting global vaccine introduction.
  • Assessment of economic viability for vaccines targeting diseases in low-income populations.

    • Main Results:

    • High investment costs for novel vaccines are difficult to recoup, especially for diseases without lucrative markets in high-income countries.
    • Lack of high-cost markets in North America and Europe deters development of vaccines for diseases like Japanese encephalitis, malaria, and dengue fever.
    • Existing economic and regulatory frameworks favor development of vaccines for diseases with broader, more profitable markets.

    Conclusions:

    • Tropical countries must establish indigenous vaccine production capabilities to ensure access to essential vaccines.
    • Innovative approaches to technology transfer are crucial for enabling local manufacturing and overcoming market access barriers.
    • Without significant changes in development incentives and support, many life-saving vaccines for tropical diseases will not reach the populations most in need.